107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China

20260 citationsJournal Articlegold Open Access

Authors

B. Liu · Harbin Medical University

J. Yao · First Affiliated Hospital of Henan University of Science and Technology

H. Zhong · Shanghai Chest Hospital

J. Li · First Affiliated Hospital of Gannan Medical University

S. Zhang · Jilin Province Tumor Hospital

Y. Sun · Shandong Tumor Hospital

H. Ge

Abstract

In HARMONi-2 study, ivonescimab significantly improved progression free survival (PFS) compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer (NSCLC), with manageable safety profile. Here we reported health-related quality of life (HRQoL) from HARMONi-2.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication Details

Published in: ESMO Open

Volume 11, pp. 106414-106414

DOI: 10.1016/j.esmoop.2026.106414

Field-Weighted Citation Impact: 0.00

Command Palette

107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China

Authors

Abstract

Topics & Keywords

Publication Details